Ishola, D., Manno, D., Afolabi, M. O., Keshinro, B., Bockstal, V., Rogers, B., . . . Watson-Jones, D. (2022). Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: A combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial. Lancet Infect Dis.
Παραπομπή Chicago StyleIshola, David, et al. "Safety and Long-term Immunogenicity of the Two-dose Heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccine Regimen in Adults in Sierra Leone: A Combined Open-label, Non-randomised Stage 1, and a Randomised, Double-blind, Controlled Stage 2 Trial." Lancet Infect Dis 2022.
Παραπομπή MLAIshola, David, et al. "Safety and Long-term Immunogenicity of the Two-dose Heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccine Regimen in Adults in Sierra Leone: A Combined Open-label, Non-randomised Stage 1, and a Randomised, Double-blind, Controlled Stage 2 Trial." Lancet Infect Dis 2022.